Letter to the Editor | Open | Published:
Emergence of babesiosis in China-Myanmar border areas
Parasites & Vectorsvolume 8, Article number: 390 (2015)
E. Vannier and P. J. Krause presented an excellent article on “Babesiosis in China, an emerging threat” in the Lancet Infectious Diseases in December 2014, which updated research on human babesiosis in China. However, a neglected and emerging issue has not been mentioned in EV & PJK’s article, that is the co-infections with B. microti and P. falciparum parasites that exist in syndemic areas, spatially in the China-Myanmar border areas of Yunnan province, China. Therefore, two important issues are addressed in here, including (i) the new emerging infections with Babesia spp. which are normally ignored in malaria endemic areas due to similarities in pathogenic morphology and clinical symptoms, (ii) additional consideration on babesiosis rather than drug-resistant malaria when anti-malaria treatment for the febrile cases in clinics fails.
To the Editor
E. Vannier and P. J. Krause presented excellent comments on “Babesiosis in China, an emerging threat”  which updated and replenished the review of “human babesiosis”  and reported human babesiosis cases in China [3–7]. Here, we would like to address a neglected and emerging issue that babesiosis has sometimes been misdiagnosed initially as malaria because of the similarities on morphology and symptoms between the two diseases. Especially, the intraerythrocytic ring form stages of Babesia microti can be misdiagnosed as ring forms of Plasmodium falciparum which are smaller than that of P. viviax, for the following three reasons. First, to date, little was known by medical doctors about the prevalence of Babesia spp. in malaria-epidemic areas, where misidentification as Plasmodium spp. is most probable. For instance, one molecular survey on febrile cases in malaria epidemic areas of southwestern China has shown that co-infections with B. microti and P. falciparum parasites exist along the China-Myanmar border in Yunnan province . Secondly, misidentification of babesiosis as drug-resistant malaria, especially in syndemic areas, may occur due to some antimalarial drugs, such as chloroquine and mefloquine, having little effect on babesiosis [7, 8]. It was also reported that two patients, with a history of malaria, were tracked following treatment with artemether plus pyronaridine in the China-Myanmar border area . Thirdly, infections with either Babesia spp. or Plasmodium spp. can cause severe diseases. The health burden imposed by both babesiosis and malaria could be substantial in these syndemic areas of China (Fig. 1), such as Yunnan province. Artemisinin-resistant P. falciparum malaria has been reported in Cambodia and the Thailand-Myanmar border . Based on a small animal model, B. microti can be responsive to artemisinin derivatives . However, in human babesiosis cases, there are still insufficient data to confirm that artemisinin derivatives are also effective to control infections of Babesia. Therefore, we strongly recommended that infection of Babesia should be excluded based on the results of laboratory-based molecular tests when the emergence of artemisinin-resistant is detected in the syndemic areas. It will help the standardization of babesiosis treatment using first choice drugs consisting of atovaquone and azithromycin and second choice drugs consisting of clindamycin and quinine . Otherwise, the co-infections of human babesiosis and malaria would undoubtedly increase the pressure of artemisinin-resistance in malaria endemic areas because of the misuse of drugs.
To promote correct identification and effective control of babesiosis and malaria in syndemic areas, clinical doctors and public health workers should be aware of the following information: (i) how to apply the molecular technologies to clearly distinguish babesiosis from malaria in order to overcome the difficulties in microscopy diagnosis due to their similarities in morphology and clinical symptoms, and (ii) to consider human babesiosis rather than drug-resistant malaria when febrile cases in anti-malaria treatment fail.
Vannier E, Krause PJ. Babesiosis in China, an emerging threat. Lancet Infect Dis. 2014;20:896–7.
Vannier E, Krause PJ. Human babesiosis. N Engl J Med. 2012;366(25):2397–407.
Zhou X, Xia S, Huang JL, Tambo E, Ge HX, Zhou XN. Human babesiosis, an emerging tick-borne disease in the People’s Republic of China. Parasites & Vectors. 2014;7(1):509.
Zhou X, Li SG, Wang JZ, Huang JL, Zhou HJ, Chen JH, et al. Emergence of human babesiosis along the border of China with Myanmar: detection by PCR and confirmation by sequencing. Emerg Microb Infect. 2014;2014(3):e55.
Sun Y, Li SG, Jiang JF, Wang X, Zhang Y, Wang H, et al. Babesia venatorum infection in Child, China. Emerg Infect Dis. 2014;20(5):896–7.
Jiang JF, Zheng YC, Jiang RR, Li H, Huo QB, Jiang BG, et al. Epidemiological, clinical, and laboratory characteristics of 48 cases of “Babesia venatorum” infection in China: a descriptive study. Lancet Infect Dis. 2014;15(2):196–203.
Zhou X, Li SG, Chen SB, Wang JZ, Xu B, Zhou HJ, et al. Co-infections with Babesia microti and Plasmodium parasites along the China-Myanmar border. Infect Dis Poverty. 2013;2(1):24.
Krause PJ. Babesiosis diagnosis and treatment. Vector Borne Zoonotic Dis. 2003;3(1):45–51.
Phyo AP, Nkhoma S, Stepniewska K, Ashley EA, Nair S, McGready R, et al. Emergence of artemisinin-resistant malaria on the western border of Thailand: a longitudinal study. Lancet. 2012;379(9830):1960–6.
Goo YK, Terkawi MA, Jia H, Aboge GO, Ooka H, Nelson B, et al. Artesunate, a potential drug for treatment of Babesia infection. Parasitol Int. 2010;59(3):481–6.
This work was supported by the National Natural Science Foundation of China (no. 81273192).
All authors declare that they have no competing interests.
XZ, XNZ participated in the design of the study and conceived the study. XZ, SX, XNZ carried out data analysis and drafted the manuscript. XZ, SX, SQY participated in the data collections. All authors read and approved the final manuscript.